

Human Vaccines: Market Research Report

<https://marketpublishers.com/r/H9F81E7134EEN.html>

Date: September 2018

Pages: 380

Price: US\$ 5,600.00 (Single User License)

ID: H9F81E7134EEN

Abstracts

This report analyzes the worldwide markets for Human Vaccines in US\$ Million by the following Product Segments: Pediatric Vaccines, and Adult Vaccines.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research.

Company profiles are primarily based on public domain information including company URLs.

The report profiles 66 companies including many key and niche players such as -

ALK Abelló A/S

Altimune, Inc.

Astellas Pharma Inc.

Bavarian Nordic

BiondVax Pharmaceuticals Ltd.

Bharat Biotech

Contents

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Data Interpretation & Reporting Level

Quantitative Techniques & Analytics

Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW

Human Vaccines: A Prelude

Growing Incidence of Infectious Diseases Drives the Global Human Vaccines Market

Total Number of Infectious Disease Covered under Vaccination

Table 1. Global Total Number of Infectious Disease Reported Cases: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 2. Diphtheria: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 3. Measles: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 4. Mumps: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 5. Pertussis: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 6. Polio: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 7. Rubella: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 8. Rubella (CRS): Total Number of Reported Cases by Geographic Region: 1980,

1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 9. Tetanus (neonatal): Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 10. Tetanus (Total): Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 11. Yellow Fever: Total Number of Reported Cases by Geographic Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Conjugate Vaccines Rule in Human Vaccines Market

Pneumococcal Vaccines – A Major Segment

Vaccine Pipeline by Major Companies

GSK Vaccine Pipeline

Merck Vaccines Pipeline (As on Aug 2018)

Pfizer Vaccines Pipeline (As on July 31, 2018)

Sanofi Vaccines Portfolio (As on Q1 2018)

Emergent BioSolutions Inc. - Vaccine Pipeline

Astellas Pharma - Vaccines

Pediatric Vaccines Dominate the Human Vaccines Market

Select Pediatric Vaccines

Adults Vaccine Market to Witness Rapid Growth, Driven by Government Initiatives

Select Adult Vaccines

Developed Markets Dominate, Emerging Regions to Exhibit the Fastest Growth

Pneumococcal Vaccines Market Set to Witness Rapid Growth

Influenza Vaccines Market: A High Growth Segment

Cancer Vaccines Market Offers Potential Opportunities

Customized Tumor-Specific Cancer Vaccines Catching On

Competitive Scenario

Table 12. Global Human Vaccines Market by Leading Player (2017): Annual Sales in US\$ Million and Market Share for GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, CSL, Mitsubishi Tanabe, and Others (includes corresponding Graph/Chart)

Table 13. Select Leading Human Vaccines Worldwide, by Sales Value: 2017 (In US\$ Million)

Vaccine Pricing: A Review

Table 14. Expanded Program of Immunization Vaccine Prices for Year 2018

3. SEGMENT OVERVIEW, GROWTH DRIVERS AND MARKET TRENDS

Combination Vaccines Market Driven by Fast Expanding Pediatric Population

List of Combination Vaccines in the US: 2018

Gardasil 9 Offers Protection against HPV for Expanded Age Group

Increasing Demand for Recombinant Vaccines

Global Cholera Vaccines Market

Further Clinical Trials Needed for an Effective Zika Vaccine

Merck's rVSV-ZEBOV Ebola Vaccine used for Ring Vaccination in Congo

Rising Dengue Cases Drive Vaccines Demand

Sanofi's Dengue Vaccine First-to-Market

Dengue Vaccine Pipeline

EMA Recommends Approval of Dengue Vaccine

Vaccine for AIDS

Staggering Global Statistics of AIDS – Opportunity Indicator

Table 15. HIV Infection Statistics Worldwide: As of 2017 (includes corresponding Graph/Chart)

Table 16. People living with HIV by WHO Region: 2017 (includes corresponding Graph/Chart)

Table 17. New HIV Infections by Region: 2017

Table 18. Worldwide HIV-related Deaths by Geographic Region: 2016-2017 (includes corresponding Graph/Chart)

Toxoid Vaccines Market

H1N1 Vaccines Market

HSV Vaccine on the Horizon

HSV Vaccines Currently in Clinical Trials

Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market

BCG Vaccines

Key TB Vaccine Candidates in the Pipeline: 2018

New Vaccine for Herpes Zoster or Shingles

Two-dose Hepatitis B Vaccine for Adults

Global Rotavirus Vaccines Market

Typhoid Vaccines Market

Measles Vaccines Market

DNA Vaccines: Engineering Growth

Mobile Money Encourages Parents for Vaccinating Children

Noninjectable Vaccines: Gain without Pain

Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines

Novel Technologies Ensure Timely Vaccine Delivery for Patients in Remote Locations

Smart mRNA Vaccines

Growing Pricing Pressure – A Major Market Deterrent

Safety Issues Come to the Fore

Novel Vaccination Guidelines Mitigate Risks Associated with Developing Shoulder Injuries

BioWarfare: Threat Perception and Preparedness

Overview of Potential Bio-Terrorist Agents

Smallpox (Variola Major)

Anthrax (Bacillus Anthracis)

Plague (Yersinia Pestis)

Botulism (Clostridium Botulinum)

Tularemia (Francisella Tularensis)

Tackling Cold Chain Issues

Trade Statistics

Table 19. Global Exports of Human Vaccines by Leading Country (2015, 2016 & 2017): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart)

Table 20. Global Imports of Human Vaccines by Leading Country (2015, 2016 & 2017): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart)

4. PRODUCT OVERVIEW

Introduction to the Concept of Immunity

Role of Vaccines in Strengthening the Immune System
Vaccines and Immunotherapy
Historical Overview of Vaccines
How it Began
So Far So Good
Successful Vaccine Introductions in the Past
Contribution of Animal Research to Vaccine Production
Types of Vaccines
Live, Attenuated Vaccines
Combination Vaccines
Killed or Inactivated Vaccines
DNA & Recombinant DNA Vaccines
Toxoids
Cellular Fractions
Conjugate Vaccines
Subunit Vaccines
Passive Immunization
Prophylactic Vaccines
Prevention Better than Cure
Prophylactic Pediatric Vaccines
Vaccination over the Years
BCG Vaccine
Growth Boosting Factors for TB Vaccines
Demand Restraining Factors for TB Vaccines
Major Issues to be addressed in the TB Vaccine Market
Hemophilus Influenza Type B Vaccine
Diphtheria/Tetanus/Pertussis Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccine
Hepatitis B Epidemiology
Measles/Mumps/Rubella Vaccines
Rotavirus Vaccines
Polio Vaccines
Varicella Vaccine
Combination Vaccines
Prophylactic Adult Vaccines
Hepatitis A Vaccine
Hepatitis B Vaccines
Key Issues Affecting the Adult Hepatitis Vaccines Market

Cholera Vaccine
Japanese Encephalitis Vaccines
Influenza Vaccines
Influenza A Virus
Influenza A (H1N1) Virus
Lyme Disease Vaccine
Pneumococcal Disease Vaccines
Meningococcal Vaccines
Rabies Vaccines
Typhoid Vaccine
Yellow Fever Vaccine
Mechanisms for Vaccine Delivery
Edible Vaccines
Oral Vaccines
Tablet Based Vaccines
Mucosal Delivery
Transdermal Patch Delivery
Storage Problems
Perfluorocarbons as Alternative to Overcome Storage Problems
Costs
Standards for Vaccine Safety and Quality

5. COMPETITIVE LANDSCAPE

5.1 Focus on Select Players

ALK – Abelló A/S (Denmark)
Altimune, Inc. (USA)
Astellas Pharma Inc. (Tokyo)
Bavarian Nordic (Denmark)
BiondVax Pharmaceuticals Ltd. (Israel)
Bharat Biotech (India)
GlaxoSmithKline Plc. (UK)
Hualan Biological Engineering Inc. (China)
Janssen Pharmaceuticals, Inc. (USA)
MedImmune (USA)
Merck Sharp & Dohme Corp., (USA)
Mitsubishi Tanabe Pharma Corporate (Japan)
Pfizer, Inc. (USA)
Sanofi Pasteur SA (France)

Serum Institute of India Pvt. Ltd. (India)

Seqirus (UK)

SK BioScience (Korea)

Takeda Pharmaceutical Company Limited (Japan)

Zydus Cadila (India)

5.2 Clinical Trials in the Vaccines Market

NIH Initiates Clinical Trial for Zika Virus Vaccine Candidate

Bavarian Nordic Publishes Positive Data for Universal RSV Vaccine from Phase 2 Extension Study

PaxVax Initiates Phase 2b Trial for Chikungunya Vaccine

Merck Plans to Initiate Studies for PCV-15 (V114)

BiondVax Initiates Phase 2 Clinical Trial of its Universal Flu Vaccine

Bavarian Nordic Announces Positive Results for Imvamune Smallpox Vaccine

Johnson & Johnson and Partners Plan to Initiate Efficacy Study for Investigational Mosaic HIV-1 Preventive Vaccine

Takeda Launches Phase 1 Clinical Trial for Zika Vaccine Candidate

Bavarian Nordic Secures Contract from the U. S. Government to Supply Freeze-Dried Imvamune Smallpox Vaccine

Bavarian Nordic Announces Positive Data for a Universal RSV Vaccine from Ongoing Phase 2 Study

Johnson & Johnson Announces Positive Clinical Data for Investigational HIV Preventive Vaccine

BiondVax Announces Positive Results from Phase 2b Clinical Trial for its Universal Flu Vaccine

CHMP Issues Positive Opinion for GSK's Synflorix Pneumococcal Vaccine

GSK Announces Positive Results for Shingles Vaccine Shingrix from Phase III Revaccination Study

Pfizer Initiates Phase 1 Clinical Trial for Investigational Group B Streptococcus Vaccine

Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine

Takeda Begins Phase 2b Trial for World's First Norovirus Vaccine

Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine Investigational Vaccine for P. vivax Malaria Enters Human Trials

5.3 Product Launches/Approvals

SK Chemicals Introduces Shingles Vaccine SKYZoster

Serum Institute of India Introduces Novel Vaccines - Rotasiil & Rabishield

Inovio Announces Positive Results from Phase 1 Trial for Zika Vaccine

PharmaJet in Partnership with Serum Institute Launches Needle-Free MMR Vaccine

Cipla Introduces Hepatitis B Vaccine in India

FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok

Sanofi's Dengue Vaccine Approved in Costa Rica

GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line

FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine

China Launches HFMD Vaccine

Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection

Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection

5.4 Recent Industry Activity

FDA Approves HPV Vaccine Usage for Adults Aged around 27 to

BiondVax Relocates to New Universal Flu Vaccine Manufacturing Facility

SK Chemicals Plans to Dominate Shingles Vaccine Market, with the Launch of SKYZoster

European Agency Proposes Approval of Sanofi's Dengvaxia to Prevent Dengue

CEPI Collaborates with Partners to Launch Lassa Vaccine

Emergent BioSolutions Acquires Cholera and Typhoid Vaccines

SK Chemicals Receives Marketing Authorization for Chickenpox Vaccine, Sky Varicella Injection

SK Chemicals Partners with Daewoong Pharmaceutical to Market and Sell Herpes Zoster Vaccine

Skchemicals Spins off Vaccine Division

Sanofi Invests in Canadian Vaccine Facility

GSK Receives European Approval for Fluarix Tetra

GSK Receives Breakthrough Therapy Designation for meningitis B vaccine Bexsero

Seqirus Joins UIVI to Advance Universal Flu Vaccine Research

Bharat Biotech Receives Prequalification for Rotavirus Vaccine, ROTAVAC from WHO

WHO Grants Prequalification for Bharat Biotech's Typbar TCV

BiondVax Receives Patent for the Universal Flu Vaccine

Altimmune Merges with PharmAthene

Aviragen Therapeutics and Vaxart Enters into a Merger Agreement

BiondVax Signs an Agreement with NIH to Conduct Phase 2 trial in the U. S. for Universal Flu Vaccine

Vedantra Pharmaceuticals Collaborates with Neon Therapeutics to Develop Novel Cancer Immunotherapies

GSK Receives Approval for Shingrix in Canada

Sanofi Plans to Inaugurate New Vaccine Production Facility in France

SK Chemicals Receives Marketing Authorization for SKYZoster

Bavarian Receives Procurement Contract for the Freeze-dried IMVAMUNE Smallpox Vaccine from BARDA

Bavarian Nordic Agrees with Janssen to Develop Vaccine against Hepatitis B virus (HBV) and the Human Immunodeficiency Virus (HIV-1)

Seqirus Invests in New Influenza Vaccine Production Facility

BiondVax Agrees to Lease Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine

Takeda and Biological E. Limited Announces Partnership to Develop Low-Cost Combination Vaccines

PaxVax and TerahVax Signs an Agreement to Market and Distribute PaxVax specialty vaccine in South Korea

PPD Announces the Expansion of Vaccine Development Laboratory

SK Chemicals and PATH Signs an Agreement to Develop New Rotavirus Vaccine

Seqirus Announces Major Advancement in Cell-Based Influenza Vaccine Technology

PaxVax Initiates a Clinical Trial to Modernized Adenovirus Vaccine

BARDA Funds Altimune for Developing First-In-Class Anthrax Vaccine Candidate, NasoShield

PaxVax Announces Partnership with NIH and DoD to Develop a New chikungunya Vaccine Program

Sanofi Pasteur and MSD Announces the End of Joint Vaccines Business in Europe

WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar

Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility

Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government

Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines

WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue

Kaketsuken to Sell Vaccines Business to Astellas

Sanofi and Merck End Joint Venture on Vaccines

GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine

Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA

6. GLOBAL MARKET PERSPECTIVE

Table 21. World Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 22. World Historic Review for Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 23. World 14-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

Table 24. World Recent Past, Current & Future Analysis for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 25. World Historic Review for Pediatric Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 26. World 14-Year Perspective for Pediatric Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

Table 27. World Recent Past, Current & Future Analysis for Adult Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 28. World Historic Review for Adult Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)

Table 29. World 14-Year Perspective for Adult Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2011, 2018 and 2024 (includes corresponding Graph/Chart)

7. REGIONAL MARKET PERSPECTIVE

7.1 The United States

A. Market Analysis

Table 30. Reported Cases and Deaths from Vaccine Preventable Diseases, United States (2010-2016)

Table 31. Reported Cases and Deaths from Vaccine Preventable Diseases, United States (2010-2016)

Pediatric Vaccines Market

Growth Drivers for US Pediatric Vaccines Market

Demand Restraining Factors for US Pediatric Vaccines Market

Commonly Administered Pediatric Vaccines

Table 32. Number of Vaccine Doses Distributed in the US: 2006-2016

Immunization Schedule for 2018

Influenza Activity and Prevention

Vaccines for Influenza Season 2018/19

List of Influenza Vaccines: For the Influenza Season 2018/19

Quadrivalent Live Attenuated Influenza Vaccine (LAIV4)

Table 33. CDC Price List for Pediatric Influenza Vaccines: 2018-2019

Table 34. CDC Price List for Adult Influenza Vaccines: 2018-2019

Product Billing Codes (CPT and Medicare) for Influenza Vaccines included for 2018/19 Season

Rise in Hepatitis A and Mumps Incidence Drives Advanced Immunization Techniques

Need for Immunization Schedule for Adults

Vaccines and Intended User Group

Vaccines Trade

Table 35. The US Exports of Human Vaccines by Country (2017 and 2016) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)

Table 36. The US Imports of Human Vaccines by Country (2017 and 2016): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)

B. Market Analytics

Table 37. The US Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 38. The US Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 39. The US 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.2 Canada

A. Market Analysis

Trade Statistics

Table 40. Canadian Imports of Human Vaccines by Country (2017 and 2016): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)

B. Market Analytics

Table 41. Canadian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 42. Canadian Historic Review for Human Vaccines by Product Segment -

Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 43. Canadian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.3 Japan

A. Market Analysis

Controversy, Confusion and Hasty Actions Mar HPV Vaccination Market

B. Market Analytics

Table 44. Japanese Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 45. Japanese Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 46. Japanese 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4 Europe

A. Market Analysis

Table 47. Number of Reported Cases of Select Infectious Diseases in the European Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Regulatory Mechanism for Vaccines in Europe

An Insight into European Influenza Vaccination Scenario

Cell-based Vaccine Production Remains Nascent, Egg-based widely used

EU Welcomes Quadrivalent LAIVs

B. Market Analytics

Table 48. European Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 49. European Historic Review for Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 50. European 14-Year Perspective for Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

Table 51. European Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 52. European Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 53. European 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.1 France Market Analysis

Table 54. French Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024

(includes corresponding Graph/Chart)

Table 55. French Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 56. French 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.2 Germany Market Analysis

Table 57. German Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 58. German Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 59. German 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.3 Italy Market Analysis

Table 60. Italian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 61. Italian Historic Review for Human Vaccines by Product Segment - Pediatric

Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 62. Italian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.4 The United Kingdom Market Analysis

Table 63. The UK Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 64. The UK Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 65. The UK 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.5 Spain Market Analysis

Table 66. Spanish Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 67. Spanish Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 68. Spanish 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.6 Russia
Market Analysis

Table 69. Russian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 70. Russian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 71. Russian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.4.7 Rest of Europe
Market Analysis

Table 72. Rest of Europe Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 73. Rest of Europe Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 74. Rest of Europe 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.5 Asia-Pacific

A. Market Analysis

Table 75. Number of Reported Cases of Select Infectious Diseases in South-East Asia Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 76. Number of Reported Cases of Select Infectious Diseases in Western Pacific Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Asian Vaccine Industry

Challenges

B. Market Analytics

Table 77. Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 78. Asia-Pacific Historic Review for Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 79. Asia-Pacific 14-Year Perspective for Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

Table 80. Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 81. Asia-Pacific Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 82. Asia-Pacific 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.5.1 China

A. Market Analysis

Large Population Offers High Potential

Growth Drivers

China – A Lucrative yet Difficult to Permeate Market

B. Market Analytics

Table 83. Chinese Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 84. Chinese Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 85. Chinese 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.5.2 India

A. Market Analysis

Market Overview

Hepatitis B Vaccine in India

Combination Vaccines

The Patent Act (Third Amendment), 2005

B. Market Analytics

Table 86. Indian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 87. Indian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 88. Indian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.5.3 Rest of Asia-Pacific Market Analysis

Table 89. Rest of Asia-Pacific Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 90. Rest of Asia-Pacific Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 91. Rest of Asia-Pacific 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.6 Latin America Market Analysis

Table 92. Latin American Recent Past, Current & Future Analysis for Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 93. Latin American Historic Review for Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes

corresponding Graph/Chart)

Table 94. Latin American 14-Year Perspective for Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin America Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

Table 95. Latin American Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 96. Latin American Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 97. Latin American 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.6.1 Brazil Market Analysis

Table 98. Brazilian Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 99. Brazilian Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 100. Brazilian 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.6.2 Rest of Latin America

Market Analysis

Table 101. Rest of Latin American Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 102. Rest of Latin American Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 103. Rest of Latin American 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

7.7 Rest of World A. Market Analysis

Table 104. Number of Reported Cases of Select Infectious Diseases in Eastern Mediterranean Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Table 105. Number of Reported Cases of Select Infectious Diseases in African Region: 1980, 1990, 2000, and 2013-2017 (includes corresponding Graph/Chart)

Nigeria: A Severely Underserved Market B. Market Analytics

Table 106. Rest of World Recent Past, Current & Future Analysis for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 107. Rest of World Historic Review for Human Vaccines by Product Segment - Pediatric Vaccines and Adult Vaccines Markets Independently Analyzed with Annual

Sales Figures in US\$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)

Table 108. Rest of World 14-Year Perspective for Human Vaccines by Product Segment - Percentage Breakdown of Dollar Sales for Pediatric Vaccines and Adult Vaccines Markets for Years 2011, 2018 & 2024 (includes corresponding Graph/Chart)

8. COMPANY PROFILES

Total Companies Profiled: 66 (including Divisions/Subsidiaries - 76)

The United States (25)

Japan (6)

Europe (15)

France (3)

Germany (2)

The United Kingdom (2)

Spain (1)

Rest of Europe (7)

Asia-Pacific (Excluding Japan) (28)

Middle East (1)

Latin America (1)

I would like to order

Product name: Human Vaccines: Market Research Report

Product link: <https://marketpublishers.com/r/H9F81E7134EEN.html>

Price: US\$ 5,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H9F81E7134EEN.html>